Clinical Impact of Rapid Identification of Positive Blood Cultures vs. Internal Laboratory Standard
1 other identifier
observational
800
1 country
1
Brief Summary
In this before-after study, different new methods for bacterial species identification from positive blood cultures will be compared towards historic controls. All samples are analyzed within the routine workflow for bacterial species identification and antibiotic resistance profiling. Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls) will be compared to patients from 2018 and 2019 with a new identification method (cases). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or Matrix-assisted Laser-Desorption/Ionization Time-of-Flight (MALDI-TOF MS). The new identification of positive blood cultures methods include (i) either the newly introduced Biofire FilmArray© Blood Culture Identification (BCID) panel or (ii) in a subset of patients whole genome sequencing (WGS) approaches.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 17, 2019
CompletedFirst Submitted
Initial submission to the registry
November 5, 2019
CompletedFirst Posted
Study publicly available on registry
November 7, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2022
CompletedMay 9, 2024
May 1, 2024
2.4 years
November 5, 2019
May 7, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to optimal antibiotic treatment in hours from positive blood cultures (hours)
Time from blood draw for blood culture testing to start of optimal antibiotic treatment (hours)
24 hours from collection of blood cultures
Secondary Outcomes (4)
Time to effective antibiotic treatment in hours from positive blood cultures (hours)
24 hours from collection of blood cultures
all-cause in hospital mortality (number)
from admission to hospital until release from hospital (approximately 30 days)
duration on ICU in days
from admission to ICU until release from ICU (approximately 20 days)
time to Gram staining and resistance profile from positive blood cultures (hours)
24 hours from collection of blood cultures
Study Arms (3)
conventional identification methods (controls)
Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.
new identification method (cases)Biofire FilmArray© BCID panel
Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
new identification method (cases) WGS approaches
Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.
Interventions
Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
Eligibility Criteria
All patients with positive blood cultures hospitalized at the university hospital Basel between August 2016 and October 2019 are included.
You may qualify if:
- patients with positive blood cultures hospitalized between August 2016 and October 2019
- documented refusal of the general consent
You may not qualify if:
- outpatients
- patients hospitalized in other hospitals
- patients with known bacteremia diagnosed in another hospital
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Division of Clinical Bacteriology & Mycology, University Hospital Basel
Basel, 4031, Switzerland
Related Publications (1)
Agnetti J, Buchler AC, Osthoff M, Helfenstein F, Weisser M, Siegemund M, Bassetti S, Bingisser R, Schaefer DJ, Clauss M, Hinic V, Tschudin-Sutter S, Battig V, Khanna N, Egli A. Identification of microorganisms by a rapid PCR panel from positive blood cultures leads to faster optimal antimicrobial therapy - a before-after study. BMC Infect Dis. 2023 Oct 26;23(1):730. doi: 10.1186/s12879-023-08732-9.
PMID: 37884860RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adrian Egli, PD Dr. med
Division of Clinical Bacteriology & Mycology; University Hospital Basel
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 5, 2019
First Posted
November 7, 2019
Study Start
October 17, 2019
Primary Completion
March 1, 2022
Study Completion
July 31, 2022
Last Updated
May 9, 2024
Record last verified: 2024-05